EVK Stock Analysis: Evonik Industries | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 9.954m EUR | 12M Return: 61.6% | DE000EVNK013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.7M
EPS Trend: 55.6%
Qual. Beats: 2
Rev. Trend: -81.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Evonik Industries AG is a German specialty chemicals company headquartered in Essen, founded in 1847, with operations spanning Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It is organized into three reporting segments: Advanced Technologies, Custom Solutions, and Infrastructure.
The Advanced Technologies segment supplies specialty polymers for medical applications, crosslinkers, hydrogen peroxide for semiconductor and paper/textile uses, silicas and silanes for automotive, tire, electronics, and cosmetics, plus amino acids (D-/L-methionine and lysine) for animal nutrition. The Custom Solutions segment provides additives and lubricant components for coatings, adhesives, sealants, polyurethane foams, and the cosmetic, cleaning, and pharmaceutical industries. The Infrastructure segment produces butadiene, MTBE, butene-1, isononanol, and DINP for use in plastics, packaging, rubber, fuels, construction, and automotive markets.
As a specialty chemicals producer, Evoniks business model is built around selling differentiated, application-specific inputs to industrial customers rather than undifferentiated commodity volumes, which typically supports higher value-added pricing and closer customer integration. The shares trade on XETRA under the ticker EVK and the company sits within the GICS Materials sector, Specialty Chemicals sub-industry.
- Methionine oversupply from China pressures animal nutrition margins
- Specialty additives pricing holds as European coatings demand weakens
- German energy and natural gas costs continue pressuring EBITDA outlook
| Net Income: 174.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.68 > 1.0 |
| NWC/Revenue: 8.59% < 20% (prev 13.02%; Δ -4.44% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.72b > Net Income 174.0m |
| Net Debt (4.68b) to EBITDA (2.41b): 1.94 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 23.20% > 18% (prev 22.56%; Δ 0.63% > 0.5%) |
| Asset Turnover: 77.88% > 50% (prev 76.92%; Δ 0.96% > 0%) |
| Interest Coverage Ratio: 5.26 > 6 (EBIT TTM 1.20b / Interest Expense TTM 229.0m) |
| A: 0.07 (Total Current Assets 5.89b - Total Current Liabilities 4.64b) / Total Assets 18.8b |
| B: 0.37 (Retained Earnings 6.93b / Total Assets 18.8b) |
| C: 0.06 (EBIT TTM 1.20b / Avg Total Assets 18.7b) |
| D: 0.75 (Book Value of Equity 8.03b / Total Liabilities 10.7b) |
| Altman-Z'' = 2.85 = A |
| DSRI: 1.14 (Receivables 1.93b/1.67b, Revenue 14.5b/14.3b) |
| GMI: 0.97 (GM 22.56% / 23.20%) |
| AQI: 0.95 (AQ_t 0.33 / AQ_t-1 0.35) |
| SGI: 1.02 (Revenue 14.5b / 14.3b) |
| TATA: -0.08 (NI 174.0m - CFO 1.72b) / TA 18.8b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of November 07, 2026, the stock is trading at EUR 21.12 with a total of 983,954 shares traded. Over the past week, the price has changed by +0.38%, over one month by +1.64%, over three months by +17.01% and over the past year by +61.57%.
Current recommended Stop Loss: 19.90 (which is 5.8% or 2.5 ATR below the current price).
Evonik Industries has no consensus analysts rating.
P/E Trailing = 59.3333
P/E Forward = 19.9203
P/S = 0.6842
P/B = 1.2443
P/EG = 6.2284
Revenue TTM = 14.5b EUR
EBIT TTM = 1.20b EUR
EBITDA TTM = 2.41b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 1.41b EUR (from shortTermDebt, last quarter)
Debt = 5.21b EUR (from shortLongTermDebtTotal, last quarter) + Leases 865.0m
Net Debt = 4.68b EUR (calculated: Debt 5.21b - CCE 533.0m)
Enterprise Value = 14.6b EUR (9.95b + Debt 5.21b - CCE 533.0m)
Interest Coverage Ratio = 5.26 (Ebit TTM 1.20b / Interest Expense TTM 229.0m)
EV/FCF = 15.92x (Enterprise Value 14.6b / FCF TTM 919.0m)
FCF Yield = 6.28% (FCF TTM 919.0m / Enterprise Value 14.6b)
FCF Margin = 6.32% (FCF TTM 919.0m / Revenue TTM 14.5b)
Net Margin = 1.20% (Net Income TTM 174.0m / Revenue TTM 14.5b)
Gross Margin = 23.20% ((Revenue TTM 14.5b - Cost of Revenue TTM 11.2b) / Revenue TTM)
Gross Margin QoQ = 22.48% (prev 24.71%)
Tobins Q-Ratio = 0.78 (Enterprise Value 14.6b / Total Assets 18.8b)
Interest Expense / Debt = 4.40% (Interest Expense 229.0m / Debt 5.21b)
Taxrate = 33.33% (92.0m / 276.0m)
NOPAT = 802.7m (EBIT 1.20b * (1 - 33.33%))
Current Ratio = 1.27 (Total Current Assets 5.89b / Total Current Liabilities 4.64b)
Debt / Equity = 0.65 (Debt 5.21b / totalStockholderEquity, last quarter 8.03b)
Debt / EBITDA = 1.94 (Net Debt 4.68b / EBITDA 2.41b)
Debt / FCF = 5.09 (Net Debt 4.68b / FCF TTM 919.0m)
Total Stockholder Equity = 8.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.93% (Net Income 174.0m / Total Assets 18.8b)
RoE = 2.16% (Net Income TTM 174.0m / Total Stockholder Equity 8.06b)
RoCE = 11.30% (EBIT 1.20b / Capital Employed (Equity 8.06b + L.T.Debt 2.59b))
RoIC = 5.33% (NOPAT 802.7m / Invested Capital 15.0b)
WACC = 4.82% (E(9.95b)/V(15.2b) * Re(5.81%) + D(5.21b)/V(15.2b) * Rd(4.40%) * (1-Tc(0.33)))
Discount Rate = 5.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 18.42 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈715.0m ; Y1≈819.6m ; Y5≈1.21b
[DCF] Fair Price = 28.92 (EV 18.2b - Net Debt 4.68b = Equity 13.5b / Shares 466.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 55.63 | EPS CAGR: 17.36% | SUE: 1.45 | # QB: 2
Revenue Correlation: -81.38 | Revenue CAGR: -3.26% | SUE: 0.72 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.38 | Chg30d=+8.57% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=1.84 | Chg30d=+3.45% | Revisions=+12% | GrowthEPS=+35.5% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=1.51 | Chg30d=+0.99% | Revisions=-12% | GrowthEPS=-17.9% | GrowthRev=-2.1%
[Analyst] Revisions Ratio: +7% (up=6, down=5)